Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Tatva Chintan Pharma Chem's EBIT per Share for the
three
months ended in Jun. 2026 was ₹9.91.
Its EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2026 was ₹31.44.
During the past 12 months, the average EBIT per Share Growth Rate of Tatva Chintan Pharma Chem was 680.50% per year.
During the past 3 years, the average EBIT per Share Growth Rate was -3.10% per year.
During the past 5 years, the average EBIT per Share Growth Rate was -23.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Tatva Chintan Pharma Chem's EBIT per Share or its related term are showing as below:
NSE:TATVA'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -60.9 Med: -3.1 Max: 43.2
Current: -3.1
During the past 8 years, the highest 3-Year average EBIT per Share Growth Rate of Tatva Chintan Pharma Chem was 43.20% per year. The lowest was -60.90% per year. And the median was -3.10% per year.
NSE:TATVA's 3-Year EBIT Growth Rate is ranked worse than 52.58% of 1337
companies
in the Chemicals industry
Industry Median: -1.1
vs NSE:TATVA: -3.10
Tatva Chintan Pharma Chem (NSE:TATVA) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Tatva Chintan Pharma Chem EBIT per Share Related Terms
Tatva Chintan Pharma Chem EBIT per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹31.44
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tatva Chintan Pharma Chem (NSE:TATVA) has a EBIT per Share of ₹31.44 as of Jun. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Tatva Chintan Pharma Chem and its competitors. According to the industry distribution chart, Tatva Chintan Pharma Chem ranks #703 out of 1337 companies in the Chemicals industry, placing it in the top 52.6%.
Is Tatva Chintan Pharma Chem's EBIT per Share too high?
Tatva Chintan Pharma Chem's current EBIT per Share is ₹31.44. Based on the distribution chart, Tatva Chintan Pharma Chem ranks #703 out of 1337 companies in the Chemicals industry, which is below the industry midpoint. Overall, Tatva Chintan Pharma Chem has a GF Score™ of 82/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Tatva Chintan Pharma Chem's EBIT per Share compare to LIN and SHW?
According to the Chemicals industry distribution chart, Tatva Chintan Pharma Chem ranks #703 out of 1337 companies for EBIT per Share. This places Tatva Chintan Pharma Chem in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Chemicals company?
A good EBIT per Share depends on the Chemicals industry context. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Tatva Chintan Pharma Chem and its competitors. Tatva Chintan Pharma Chem's current EBIT per Share is ₹31.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tatva Chintan Pharma Chem stock overvalued right now?
Based on GuruFocus' analysis, Tatva Chintan Pharma Chem (NSE:TATVA) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹1,502.93, compared to a current price of ₹1,788.20 — trading 19% above its estimated fair value. The current EBIT per Share is ₹31.44. Tatva Chintan Pharma Chem's overall GF Score™ is 82/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Tatva Chintan Pharma Chem (NSE:TATVA), the current EBIT per Share is ₹31.44 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tatva Chintan Pharma Chem (NSE:TATVA) Overvalued in 2026?
Based on GuruFocus' analysis, Tatva Chintan Pharma Chem stock appears to be overvalued.
The current stock price of ₹1,788.20 is trading 19% above its estimated GF Value™ of ₹1,502.93.
GuruFocus considers Tatva Chintan Pharma Chem to be Modestly Overvalued.
Key valuation signals for NSE:TATVA:
EBIT per Share: ₹31.44
GF Value™: ₹1,502.93 vs. price of ₹1,788.20 (19% above fair value)
No single metric tells the full story. See the NSE:TATVA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tatva Chintan Pharma Chem Ltd is a specialty chemicals manufacturing company engaged in the manufacturing and selling of specialty chemicals, Pharma and Agro intermediates, Quaternary Compounds, and Quats. The company's product portfolio includes structure-directing agents, phase transfer catalysts, electrolyte salts for supercapacitor batteries, pharmaceutical and agrochemical intermediates and other specialty chemicals. The company sells its products in domestic as well as overseas markets, with the majority of revenue coming from overseas markets.
82GF Score
Get the complete analysis for NSE:TATVA
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:TATVA has been successfully added to your 
